Care focuses on medical evaluation, patient education, personalized planning, and safe provider-guided recommendations
The SUSTAIN series (semaglutide) documented 10-17% weight loss, while SURMOUNT series (tirzepatide) documented 15-22% weight loss over 68 weeks
Tirzepatide occupies the middle ground Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed a reporting odds ratio of 1.73, elevated but lower than semaglutide
Higher-risk groups include older adults, those following vegetarian or vegan diets, patients taking metformin or long-term proton pump inhibitors, and individuals with a history of gastrointestinal surgery or conditions such as pernicious anaemia or coeliac disease
Molecular cell biology , 22 (2), 119-141
The key agents you will see discussed throughout this post include: Semaglutide (Ozempic/Wegovy/Rybelsus): Weekly subcutaneous or once-daily oral